The efficacy of specifically targeted anti-viral therapy for hepatitis C virus (HCV) (STAT-C), including HCV protease and polymerase inhibitors, is limited by the presence of drugspecific viral resistance mutations within the targeted proteins. Genetic diversity within these viral proteins also evol
β¦ LIBER β¦
Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy
β Scribed by Liana Gheorghe; Bogdan Cotruta; Viorel Trifu; Cristina Cotruta; Gabriel Becheanu; Cristian Gheorghe
- Book ID
- 110878471
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 686 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0011-9059
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Hepatitis C virus drug resistance and im
β
Silvana Gaudieri; Andri Rauch; Katja Pfafferott; Eleanor Barnes; Wendy Cheng; Ge
π
Article
π
2008
π
John Wiley and Sons
π
English
β 368 KB
Mechanisms of drug resistance to current
β
Jean-Michel Pawlotsky
π
Article
π
2004
π
Current Science Inc.
π
English
β 453 KB
Prophylactic Citalopram Treatment in Hep
β
Thomas N. Wise
π
Article
π
2010
π
Springer
π
English
β 59 KB
Relationship between the interleukin-28b
β
Dennis Eurich; Sabine Boas-Knoop; Martin Ruehl; Maria Schulz; Esperanza D. Carri
π
Article
π
2011
π
John Wiley and Sons
π
English
β 293 KB
Up to 30% of liver transplants will develop graft cirrhosis within 5 years after liver transplantation (LT) due to recurrent HCV-infection forwarding accelerated graft damage. Genetic variants of cytokines involved in the immune response may contribute to the degree of graft inflammation, fibrosis p